Combination immunotherapy: the emerging treatment that removes cancer's "cloak of invisibility". Torjesen Ingrid et al. BMJ (Clinical research ed.) 2019 Apr 365l1824

Main|Search|PHGKB


Last Posted: May 04, 2019

---

• Combination immunotherapy: the emerging treatment that removes cancer's "cloak of invisibility".
  Torjesen Ingrid et al. BMJ (Clinical research ed.) 2019 Apr 365l1824
• Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
  A Haslam et al, JAMA Network Open, May 3, 2019
• Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
  Bristow Robert G et al. The Lancet. Oncology 2018 19(5) e240-e251
• Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
  Friedlaender Alex et al. Frontiers in oncology 2019 9166
• Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
  Singal Gaurav et al. JAMA 2019 Apr 321(14) 1391-1399
• Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
  Singh Ritu R et al. Cancer treatment reviews 2019 Mar 7527-38
• Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
  Ricciuti Biagio et al. Journal for immunotherapy of cancer 2019 Mar 7(1) 87
• Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing.
  Dong Jingsi et al. Frontiers in pharmacology 2019 10230
• Hope and challenge: Precision medicine in bladder cancer.
  Su Hongwei et al. Cancer medicine 2019 Mar
• Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges.
  Duraturo Francesca et al. Oncology letters 2019 Mar 17(3) 3048-3054

more